Dr Kim

Dr Kim Professor in Epidemiology and Statistics,
Medical Epidemiologist and Statistician,
Research Consultant
Fellow of the American College of Epidemiology (FACE)

Noted
25/01/2026

Noted

💬 Viewpoint: The Joint Commission and Coalition for Health AI have issued guidance on responsible use in health care, but without a unified evaluation system, US hospitals face liability and efficiency challenges as AI adoption expands.

https://ja.ma/45uTx7U

25/01/2026

According to new research, Asia bore two-thirds of the global burden of chronic respiratory disease (CRD) and accounted for 67% of disability-adjusted life years (DALYs, or years of healthy life lost) in 2023. Of the total burden, India contributed 43% of the DALYs and China contributed 28%, with these large shares attributed to population size and persistently high rates of CRD.

Understand trends and learn more about key findings in the paper published today in The Lancet Respiratory Medicine: http://ms.spr.ly/6189Q8KNJ

20/01/2026

Reflections on Our DrPH Candidates' Statistical Analysis Work: Empowering Reproducible Analysis

I am pleased to share the recent work produced by our Doctor of Public Health (DrPH) candidates at the School of Medical Sciences, Universiti Sains Malaysia. These assignments represent the culmination of their training in applied multivariable analysis using R programming.

The DrPH programme is a three-year professional doctorate that prepares candidates for recognition as Public Health Medicine specialists in Malaysia including at Ministry Of Health, Malaysia (KKM). As part of our curriculum, we have integrated R programming and modern data science workflows, with students working in RStudio IDE and Positron IDE. Our vision is to develop the next generation of leaders in health data analysis and epidemiological modelling for Malaysia.

Selected Student Assignments: The following examples demonstrate the analytical competencies our candidates have developed:

https://posit-connect.kk.usm.my/content/6f3c7710-f751-495d-baf4-80ec79ab0cc1/logistic.html

https://posit-connect.kk.usm.my/content/d5bb6a3a-1e01-48c1-8a67-95e0882bf1b9/MLR%20Assignment.html

https://posit-connect.kk.usm.my/content/2987b23e-f1f1-47ef-a116-90260349bf05/Linear%20CA_edited_030126.html

https://posit-connect.kk.usm.my/content/93a344c5-b215-462d-a52c-91272bc7858c/Logistic%20Regression%20Analysis%20of%20Depression.html

Acknowledgements:

I extend my sincere gratitude to the R open-source community and to Posit for their continued support. Their provision of Posit Connect has enabled us to deploy student work in a professional environment, bridging the gap between academic training and real-world application.

For inquiries regarding collaboration opportunities or training programmes for your organisation or team, please contact me directly.

cc Kim Imran

18/01/2026
Exciting Update: Official Visit to Kunming Medical University, ChinaI'm delighted to share highlights from my recent thr...
18/01/2026

Exciting Update: Official Visit to Kunming Medical University, China
I'm delighted to share highlights from my recent three-day official visit to Kunming Medical University (KMU), the largest medical university in Kunming, China, with an impressive workforce of nearly 7,000 staff members.

Our Visit in Brief:

🎓 Day 1 - We were graciously hosted at the KMU campus, where we had the opportunity to tour their facilities and engage in meaningful discussions about medical education and research excellence.

🏥 Day 2 - We visited KMU's Second Affiliated Hospital, a remarkable 6,000-bed tertiary care facility. The visit included a detailed presentation on their clinical services and an extensive tour of the hospital.

I was honored to present about our School of Medical Sciences at Universiti Sains Malaysia, sharing our achievements in research and education.

What's Next?

We are taking concrete steps to formally establish the USM-KMU Medical and Health Research Collaboration Group. This partnership will enable:

✅ Skill and knowledge transfer between our institutions
✅ Joint research projects and publications
✅ Collaborative grant applications
✅ Enhanced opportunities for our students and faculty

This collaboration marks an important milestone in expanding USM's global research network and strengthening our commitment to advancing healthcare through international partnerships.

Looking forward to the innovative research and meaningful outcomes this partnership will generate! 🌟

cc Kim Imran

Berkongsi Report Card oleh Top 2% Scientist. It will not be possible without the support and understanding from Jue, par...
28/12/2025

Berkongsi Report Card oleh Top 2% Scientist.

It will not be possible without the support and understanding from Jue, parents, sons, family and collaborators.

Semoga lebih ramai penyelidik-penyelidik di Malaysia mencapai tahap lebih tinggi.

Link: https://topresearcherslist.com/Home/Profile/879426

CC Kim Imran

Kecelaruan Menterjemah Evidence-Based Medicine dan Kesombongan Melabel Kesan Baik Perubatan dan Pengubatan Baru Sebagai ...
24/12/2025

Kecelaruan Menterjemah Evidence-Based Medicine dan Kesombongan Melabel Kesan Baik Perubatan dan Pengubatan Baru Sebagai Satu Testimoni Sahaja.

Tahun 2000, saya bermula mendalami bidang epidemiologi perubatan. Sebagai pelajar epidemiologi, kami di ajar untuk menjiwai Evidence Based Medicine. Kemudian sebagai pakar perubatan kesihatan awam dan pakar epidemiologi (Fellow of the American College of Epidemiology) saya berterusan meletakkan kepentingan bukti dalam pengubatan dan pengawalan penyakit dan kurang upaya (disability). Selama 25 tahun saya melihat, mendalami, menjiwai dan menguasai apa itu epidemiogi, apa itu evidence, apa itu evidence based medicine termasuk kekuatan dan kelemahannya.

Dan tidak saya sahaja yang berterusan meletakkan evidence based medicine sebagai neraca dalam menentukan apakan rawatan, intervensi dan kawalan yang paling sesuai, ramai rakan-rakan saya dan pelajar-pelajar saya juga menggunakan. Malangnya, ramai juga dari golongan profesional perubatan termasuk rakan-rakan saya tanpa mereka sedari (atau mereka sedari) menterjemah dengan salah atau tidak ikhlas atau terlalu membuta tuli dan taaksub. Didapati pemahamam mereka salah mengenai evidence based medicine.

Sangat selalu, mereka ini yang "dikatakan" pakar-pakar walauun betul menggunakan evidence based medicine tetapi menyeleweng dan menyalah gunakan dan memudah mudah kan penterjemahan bukti, sekali lagi, mungkin dengan sedar atau tidak sedar. Bila dihadap dengan inovasi-inovasi perubatan dan pengubatan yang mereka tidak biasa atau tidak arif (jahil), maka untuk menutup kejumudan dan kecetekan ilmu mereka, maka alasan-alasan yang di sandarkan kepada keperluan evidence based medicine di gunakan.

Maka di label kan pengguna tersebut sebagai penipu dan mengejek dengan alasan itu semua testimoni. Tanpa mereka sedar bahawa testimoni itu adalah bernilai. Nama yang lebih glamour adalah personal anecdotes. Dan sebenarnya, bukan sahaja orang biasa yang ada personal anecdotes, malah professional perubatan pun banyak menggunakan personal anecdotes, iaitu pengalaman positif memberikan rawatan kepada pesakit menyebabkan professional perubatan menyarankan rawatan yang sama untuk pesakit yang lain. Jadi nya di sebelah pengguna atau orang awam, ada testimoni malah untuk professional perubatan pun ada testimoni mereka sendiri, malah sangat kerap terjadi.

Di sini saya nak bawa satu contoh kesan kedangkalan dalam menilai hasil kajian akibat terpedaya dengan kesan yang di panggil "average effect". Saya bagi satu contoh yang sangat mudah. Cuba paham contoh seperti berikut; katakan ada 20 kajian (n=20) kepuasan meminum kopi cap A. Dari 20 kajian, 10 kajian yang menunjukkan majoriti pengguna merasa sedap (50%), dan 10 kajian lagi majoriti pengguna mengatakan tidak sedap (50%). Adakah boleh di simpulkan bahawa rasa dari minum kopi cap A adalah sederhana sahaja (tidak sedap dan tidak juga tidak sedap, kerana 50% dan 50%).

Itu kesimpulan yang salah. Kesimpulan yang benar adalah 50% kajian menunjukkan majoriti pengguna kopi A merasa sedap minum kopi A dan 50% kajian menunjukkan majoriti pengguna tak s**a kopi A. Yang sedap tetap sedap dan yang tak sedap itu tak sedap. Itu adalah fakta. Langkah seterusnya adalah melihat kenapa ada kesan berbeza - adakah di sebabkan faktor makanan yang di makan oleh peserta sebelum itu yang mengubah rasa kumpulan , atau mungkin kesan campuran kopi yang berbeza, dan lain-lain.

Selalunya alasan mereka adalah, kami adalah pakar perubatan dan apa-apa berkait dengan perubatan mesti ada pembuktian termasuk semua perubatan dan pengubatan mesti dari randomized clinical trials atau dari SR dan meta analysis. Pakar-pakar ini menolak segala kesan atau impak atau perubahan positif yang di rasai selepas mengamalkan inovasi atau solusi perubatan dan pengubatan baru oleh seseorang individu atas alasan kesan, impak dan perubahan itu hanyalan khayalan yang disebabkan oleh kesan plasebo.

Padahal mereka harus sedar, kesan plasebo itu adalah kesan baik yang dirasai oleh pesakit atau pengguna dari penggunaan bahan atau inovasi atau solusi perubatan dan pengubatan yang tidak aktif. Jika solusi perubatan dan pengubatan itu memang mengandungi mekanisme untuk memberikan kebaikan kepada tubuh badan pengguna maka terma kesan plasebo itu tidak lagi sesuai untuk di gunakan.

Sebagai kesimpulan, jika saya seorang (N=1) menggunakan satu kaedah pengubatan dan perubatan yang baru dan ternyata ada kesan yang baik kepada saya, maka kesan itu adalah valid dan benar. Jangan para pakar ini datang dan disebabkan kejumudan mereka dan kedangkalan ilmu mereka, maka di label saya ini seorang yang mengamalkan pseudoscience. Jangan di bawa keputusan-pekutusan kajian-kajian RCT dan menggunakan alasan evidence-based medicine bagi menunjukkan ke"authority"an mereka dan terus menidakkan kesan positif yang dirasakan oleh saya (atau pengguna lain). Jika anda sebagai pengguna merasa kesan positif, maka kesan itu kesan yang betul dan sesiapa so called profesional perubatan atau pakar-pakar mana yang datang dan mengatakan itu khayalan (dan lebih parah lagi mengatakan itu plasebo effect), maka profesional perubatan pakar-pakar itu yang sebenarnya naif.

Yang penting kepada professional perubatan adalah meningkat kefahaman ilmu evidence based anda dan memberikan informasi tanpa bias kepada pesakit atau pengguna. Nyatakan kepada pengguna dan pesakit, apa kebaikan dan apa keburukan kesan dari pengambilan sesuai rawatan dan pengubatan baru. Ajarkan kepada mereka supaya melihat kepada kesan sampingan dan mendapatkan rawatan awal dengan segera. Teruskan TCA pesakit dan selalu lakukan ujian saringan dan ujian bagi melihat kesan kepada fisiologi dan chemistry badan. Selagi mana pengguna atau pesakit merasa kesan positif hasil penggunaan rawatan dan pengubatan yang baru dan kesan pemeriksaan dan lab tests masih OK atau tidak merudum, maka biarkan mereka mengamalkannya. Para professional juga seharusnya lebih banyak membaca dan lebih kritikal dalam memahami sains dalam evidence based medicine.

Seperti kata Professor Guyatt, Bapa Evidence Based Medicine "N=1 trials eliminate the "average effect" error by measuring the individual's actual response." Jika anda belum pernah dengar nama Guyatt, anda masih bukan epidemiologist.

Tontoni video ini di https://www.youtube.com/watch?v=xFQdiCQ5FD0

1. The Confusion of the Evidence Hierarchy
Professor Guyatt critiques the standard evidence pyramid (often found on Wikipedia or in medical schools) for being "fundamentally confusing" and "totally confused". He identifies three main areas of confusion:

Mixing Processing with Design: Standard pyramids place "Systematic Reviews" at the top, but Guyatt explains that a systematic review is just a method of aggregation. A systematic review of low-quality case reports is still low-quality evidence; it does not magically become "top tier" just because it is a review.

One Size Does Not Fit All: There isn't one hierarchy. The best design for therapy (Randomized Controlled Trials) is different from the best design for prognosis or diagnosis.

Ignoring Values and Preferences: The pyramid suggests evidence alone tells you what to do. Guyatt emphasizes that evidence only provides "upsides and downsides"; the final decision must be based on patient values and preferences.

2. The Weakness of "Average Effects"
A major theme of the video is the limitation of large-scale Randomized Controlled Trials (RCTs) when applied to individuals. Guyatt explains that:

Population vs. Individual: Evidence about groups can only tell you about groups. Because of human variability, an "average effect" found in a study of 1,000 people might not apply to you at all.

Interpreting the Mean: A treatment might show a positive average effect, yet many individuals in that same study may have experienced no benefit or even harm.

The Problem of Generalizability: Most trials are done on specific populations (e.g., young, white adults). Applying those "average" results to an 80-year-old or someone of a different racial background requires "physiologic reasoning" and guesswork because the direct evidence doesn't exist for that specific individual.

3. Justifying N=1 as the "Gold Standard"
Professor Guyatt justifies the N=1 randomized trial (where a single patient alternates between a treatment and a placebo in a blinded, rigorous way) as the true pinnacle of evidence for treatment.

Personalization: The ultimate goal of medicine is to find out what works for this specific patient. N=1 trials eliminate the "average effect" error by measuring the individual's actual response.

Falsifying Beliefs: Guyatt shares an example of patients who believed statins caused them muscle pain. Through N=1 trials, it was proven the pain was unrelated to the drug, allowing them to continue life-saving treatment.

Why It’s Not Used: Despite being the "best evidence," Guyatt admits N=1 trials have "failed" to take over medicine simply because they are a "logistical hassle" for busy clinicians.

cc Kim Imran

Gordon Guyatt coined the term "Evidence-Based Medicine" in 1991 and together with David Sackett and others he founded the EBM movement, formally proclaimed i...

Selesai sudah:RESEARCH WEBINAR: ROLE OF AI IN HEALTH PRACTICE AND RESEARCH slides ada di https://bit.ly/aicyberjaya OVER...
24/12/2025

Selesai sudah:
RESEARCH WEBINAR: ROLE OF AI IN HEALTH PRACTICE AND RESEARCH

slides ada di https://bit.ly/aicyberjaya

OVERVIEW

This webinar offers an introduction to how Artificial Intelligence (AI) is transforming health practices and research. Participants will explore core concepts of AI in healthcare, research design considerations, and best practices in academic publishing. The session also equips participants with practical insights to enhance research quality and recommends approaches for using AI responsibly in academic research and publications.

WHO SHOULD JOIN
• Early career researchers • Postgraduate students • Academicians and researchers

BENEFITS • Gain a foundational understanding of AI applications in health research and practice • Learn about two types of Artificial Intelligence (AI); Predictive AI and Generative AI • Learn about the range of AI tools available for health research, including platforms for data analysis, predictive modelling, natural-language processing, and generative content creation. • Learn how AI can enhance research including data analysis and writing.

cc Kim Imran

Kolaborasi Besar dan Signifikan Pada Tahun 2026.InsyaAllah, satu projek kolaborasi yang penting akan bermula pada tahun ...
12/12/2025

Kolaborasi Besar dan Signifikan Pada Tahun 2026.

InsyaAllah, satu projek kolaborasi yang penting akan bermula pada tahun 2026. Idea dan persiapan projek ini telah bermula lebih dari setahun namun akibat faktor-faktor luar kawalan di peringkat antarabangsa, maka ia nya tertunda.

Namun, semua nampaknya sudah tersedia. Alhamdulillah, saya bersyukur mempunyai rakan-rakan penyelidik yang berpengalaman, komited dan excellent team players dari UKM dan UNIMAS. Kami akan cuba buat yang terbaik demi meningkatkan kualiti kesihatan dan kesejahteraan terutama anak-anak kita di Malaysia.

Saya juga bersyukur kerana di beri sekali lagi kepercayaan oleh organisasi dari UK untuk mengetuai projek ini. Semoga Allah SWT mempermudahkan urusan kami semua dalam melaksanakan tanggung jawab ini.

cc Kim Imran

Research in Stroke. Had a good meeting with Prof Valery Feigin, one of the world top neurologists. We have worked togeth...
02/12/2025

Research in Stroke.

Had a good meeting with Prof Valery Feigin, one of the world top neurologists. We have worked together before, and I am pleased to be part of this new endeavour.

cc Kim Imran

Assalamualaikum and Selamat Sejahtera,We cordially invite you to join a webinar that bridges epidemiological research wi...
10/11/2025

Assalamualaikum and Selamat Sejahtera,

We cordially invite you to join a webinar that bridges epidemiological research with practical public health applications in colorectal cancer control.

Event Details:
📅 Date: Monday, 17 November 2025 |
🕐 Time: 14:00 (Malaysia Time, UTC+8)
💰 Registration: FREE |
🎓 CPD Points: Available for Malaysian Medical Association members

About the International Epidemiological Association (IEA):
The IEA is the world's leading professional association for epidemiologists, fostering global collaboration in epidemiological research and practice. With regional networks spanning all continents, the IEA promotes excellence in epidemiological science, supports capacity building, and advances evidence-based public health policy worldwide.

Early Career Epidemiologists Programme:
The IEA recognizes the vital importance of nurturing the next generation of epidemiological leaders. Through its Early Career Epidemiologists initiative, the association provides mentorship, networking opportunities, and platforms for emerging researchers to share innovative approaches.

Webinar Synopsis:
Colorectal cancer represents the third most common malignancy globally, characterized by substantial geographical and demographic variations in incidence and mortality rates. This webinar explores how precision public health is revolutionizing our approach to this significant health challenge.
Traditional diagnostic approaches—including colonoscopy, f***l immunochemical testing, and imaging modalities—are being enhanced through precision public health frameworks that leverage genomic data, electronic health records, and population-based surveillance systems to identify high-risk populations and optimize prevention strategies.

Why Attend?
Whether you're a clinician, public health practitioner, researcher, or postgraduate student, this session offers valuable insights into:
Contemporary epidemiological approaches to colorectal cancer
Precision public health strategies for cancer control
Practical applications of big data and predictive analytics
Regional perspectives and collaborative opportunities from the Western Pacific Career development pathways in epidemiological programme.

Distinguished Speakers:
Professor Dr. Azmawati Mohammed Nawi
Faculty of Medicine, National University of Malaysia
Topic: Colorectal Cancer in the Era of Precision Public Health

International Contributors:

Assoc Prof Brigid Lynch - IEA Western Pacific Regional Councillor, Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia

Assoc Prof Bomi Park - IEA Western Pacific Early Career Epidemiologist, Department of Preventive Medicine, College of Medicine, Chung-Ang University, Seoul, Korea

Moderated by:
Professor Dr. Kamarul Imran Musa, School of Medical Sciences, Universiti Sains Malaysia

Programme Schedule:
14:00 - Welcoming Remarks (Prof Kamarul Imran Musa)
14:05 - Introduction to IEA (Assoc Prof Brigid Lynch)
14:10 - Early Career Epidemiologists (Assoc Prof Bomi Park)
14:15 - Colorectal Cancer in the Era of Precision Public Health (Prof Azmawati Mohammed Nawi)
15:45 - End

Who Should Attend?
✓ Medical practitioners and specialists
✓ Public health professionals
✓ Epidemiologists and biostatisticians
✓ Healthcare researchers
✓ Cancer screening and prevention programme coordinators
✓ Postgraduate students in medicine, public health, and epidemiology
✓ Early career researchers interested in cancer research

Registration:
Secure your spot today! Scan the QR code in the attached poster or register at: https://usm-cmr.webex.com/weblink/register/r5eac72a3386f8d183d89a852eeb35f93

Platform: Webex (link will be provided upon registration)

Organized by:

International Epidemiological Association (IEA)
Malaysian Association of Epidemiology (MAE)
School of Medical Sciences, Universiti Sains Malaysia (USM)

This is an excellent opportunity to enhance your knowledge in cancer epidemiology, learn about precision public health approaches, and connect with leading experts in the field.

Please feel free to share this invitation with colleagues who might benefit from attending.

https://www.youtube.com/watch?v=mFMW7WrlmeI(Disalin dari YouTube Hooray HPUSM)Dalam kepesatan pembangunan dunia kesihata...
30/10/2025

https://www.youtube.com/watch?v=mFMW7WrlmeI

(Disalin dari YouTube Hooray HPUSM)

Dalam kepesatan pembangunan dunia kesihatan, teknologi memainkan peranan besar dalam menyelamatkan nyawa dan mempercepat rawatan. Dalam episod kali ini, kami membincangkan bagaimana pendigitalan kesihatan di Malaysia membuka ruang kepada inovasi seperti aplikasi CaknaStrok, dibangunkan oleh USM untuk membantu pengesanan dan pengurusan strok secara lebih awal dan efisien.

🎧 Sertai kami dalam podcast ini untuk memahami bagaimana teknologi dapat membawa perubahan sebenar dalam penjagaan kesihatan rakyat Malaysia.

Dalam kepesatan pembangunan dunia kesihatan, teknologi memainkan peranan besar dalam menyelamatkan nyawa dan mempercepat rawatan. Dalam episod kali ini, kami...

Address

Kota Bharu
16150

Alerts

Be the first to know and let us send you an email when Dr Kim posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Dr Kim:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram